Be sure to ask your pharmacist not to substitute another card for ours as we are confident we offer the highest savings possible.
Accepted at over 59,000 pharmacies nationwide including:
Cetuximab (Erbitux) is a chimeric (mouse/human) monoclonal antibody, an epidermal growth factor receptor (EGFR) inhibitor, given by intravenous infusion for treatment of metastatic colorectal cancer and head and neck cancer. When growth factors bind to their receptors on the surface of the cell, the receptors give a signal that causes cells to divide. Some cancers are caused by mutated receptors that give a signal to divide even without growth factor. That causes the cells to divide uncontrollably. Cetuximab binds to such receptors and turns off that signal. The EGFR sends a signal down a pathway (see MAPK) that includes another protein, KRAS (also spelled K-ras). In some cancers, the EGFR is mutated, and is present to a larger or smaller degree. In these cancers, the KRAS protein may also be "wild" or mutated. If mutated, KRAS sends a signal to divide uncontrollably, even if EGFR has been blocked by cetuximab. Cetuximab binds to EGFR and turns off the uncontrolled growth in cancers with EGFR mutations (although in practice, studies have shown that the effect of cetuximab does not actually depend on the amount of EGFR receptor protein found on the cancer cells). However, if the KRAS protein in mutated, cetuximab has been found not to work, because the mutated KRAS gene downstream is causing the problem by continuously sending a growth signal (the KRAS protein) and this mutated gene now does not respond to the EGFR receptor. Therefore, before cetuximab is used, the standard of care is that the KRAS gene in the cancer cells is tested for mutation. If KRAS is normal (wild type), cetuximab might work. But if KRAS is mutated, indications are that cetuximab (and also panitumumab) will not work, because the mutated KRAS gene continuously sends a KRAS protein signal to divide, even when cetuximab has turned the earlier EGFR signal off. A genetic test for the KRAS mutation was approved by the FDA as an indication for Erbitux treatment of colon cancer in July, 2009 (this also applied to the EGFR antibody panitumumab) This was the first genetic test to guide treatment of cancer.
Wikipedia contributors. "Erbitux" Wikipedia, The Free Encyclopedia. Wikipedia, The Free Encyclopedia, Jul 7, 2012. Web. Jul 10, 2012.
Important Note - The information on this website is intended to supplement, not substitute for, the expertise and judgment of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that use of the drug is safe, appropriate, or effective for you. Consult your healthcare professional before using this drug.
This prescription discount card cannot be used in conjunction with insurance. However, some members find they save more when using the card rather than there prescription coverage.
This Erbitux discount should not be confused with a Erbitux coupon while they are essentially the same this discount card only needs to be handed to your pharmacist once and will provide continuous savings every time your prescription is filled. The only time you will need to use it again is if you change pharmacies.
Currently we do not have any available, however you can receive an instant discount at your pharmacy with our Erbitux discount card. Print one instantly
|Top Prescription Discounts|
|Vyvanse Coupon||Tazorac Coupon||Lo Loestrin Fe Coupon||Savella Coupon|
|Nuvigil Coupon||Vigamox Coupon||Epipen Coupon||Patanase Coupon|
|Effient Coupon||Ciprodex Coupon||Vaniqa Coupon||Focalin Coupon|
|Bystolic Coupon||Moxeza Coupon||Xarelto Coupon||Androgel Coupon|
|Lotemax Coupon||Epiduo Coupon||Zymaxid Coupon||Janumet Xr Coupon|
|Aczone Coupon||Dymista Coupon||Femring Coupon||Benzefoam Coupon|